A/Prof Tim Clay on Twitter: "First side by side of KN407 vs ImPower131 survival curves Usual cross trial comparison disclaimer Note different chemo backbone possible in KN407 #ASCO18 https://t.co/ofXP1S9WvN" / Twitter
The design and evaluation of hybrid controlled trials that leverage external data and randomization | Nature Communications
Vikram Keeshara on Twitter: "Blenrep through - Ide-cel at the gate A cross-trial comparison of the data from Phase 2 trials of GSK's Blenrep, and BMS and bluebird bio's Ide-cel for the
Cross-trial comparisons: A source of confusion, use, or both in the management of patients with atrial fibrillation? - ScienceDirect
Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial | Journal of Nuclear Medicine
Abbvie's Jak measures up nicely in eczema | Evaluate
Randomized controlled trial - Wikipedia
ALKi in Management of NSCLC: Resistance Mechanisms, PFS Cross Trial Comparison, and Safety Profiles | VuMedi
2: Cross trial comparison is not recommended and should occur with caution | Download Scientific Diagram
SSAT - REAL WORLD SCENARIO: CROSS REGIMEN AS PREOPERATIVE THERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Should Lilly also take on Merck in lung cancer? | Evaluate
Cross-over trials
Vikram Keeshara on Twitter: "Blenrep through - Ide-cel at the gate A cross-trial comparison of the data from Phase 2 trials of GSK's Blenrep, and BMS and bluebird bio's Ide-cel for the
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial - The Lancet Oncology
CLEAR Trial: Is Lenvatinib Plus Pembrolizumab the Best First-Line Immunotherapy Doublet in Metastatic Renal Cell Carcinoma? - The ASCO Post
Cross-trial comparisons: A source of confusion, use, or both in the management of patients with atrial fibrillation? - ScienceDirect
2: Cross trial comparison is not recommended and should occur with caution | Download Scientific Diagram
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial - The Lancet Oncology
Lilly takes on Novo in obesity | Evaluate
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial - The Lancet Oncology
Best Practices in Genitourinary Oncology Navigation: Renal-Cell Carcinoma - Journal of Oncology Navigation & Survivorship
EGFR- and ALK-targeted treatment: present and future - memoinOncology
Crossover trials: what are they and what are their advantages and limitations? - Students 4 Best Evidence
